Skip to main content

ESTUDIO PROSPECTIVO MULTICENTRICO PARA EXPLORAR LA RELACION ENTRE LAS INFECCIONES DEL TORRENTE SANGUINEO POR ENTEROCOCCUS FAECALIS Y LA NEOPLASIA COLORRECTAL (PROYECTO ENTEROCOLONUS-GAMES).

PI19/01898

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUTO INV. BIOMEDICA DE LLEIDA. FUNDACION DR. PIFARRE (IRBLLEIDA)
Execution centre INSTITUTO INV. BIOMEDICA DE LLEIDA. FUNDACION DR. PIFARRE (IRBLLEIDA)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Needs assessment for creation of a platform trial network in metabolic-dysfunction associated steatohepatitis

  • Sena, Elena|||0000-0003-1220-5639
  • Tacke, Frank|||0000-0001-6206-0226
  • Anstee, Quentin M.|||0000-0002-9518-0088
  • Di Prospero, Nicholas
  • Skalshøi- Kjær, Mette
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Rivera Esteban, Jesús|||0000-0003-4357-8817
  • Jiménez-Masip, Alba
  • Bañales, Jesús M.
  • Martínez-Gómez, María
  • Koenig, Franz
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
  • Ratziu, Vlad
  • Pericàs, Juan M.|||0000-0002-3645-3293
The EU Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) project (IMI2-853966) aimed to develop tools to establish integrated research platforms (IRP) for conducting adaptive-design trials in various diseases, including metabolic-dysfunction associated steatohepatitis (MASH). One essential component of a successful MASH IRP is a robust and reliable Clinical Research Network (CRN). Herein, we outline the required elements and anticipated steps to set-up such a CRN. We identified European clinical research sites that could potentially serve as the foundation for MASH IRP and a CRN. A survey was sent to sites to assess their interest in joining a CRN, their familiarity with platform trials, and their capacity to participate in a future MASH IRP. A total of 141 investigators were invited to participate in the survey, and 40% responded. More than half of the answers (52%) identify MASH with advanced fibrosis (F3-4) as the subpopulation with the greatest unmet need. Regarding the difficulty in identifying candidates for trials, 65% find it is moderately difficult and 30% very difficult. Most respondents (94%) believe that a platform trial could offer substantial benefits to patients. Nearly all researchers express interest in participating in a platform trial (78%), with 22% indicating their interest would be contingent on initial industry funding. While preliminary, our findings on responding sites are encouraging for the potential establishment of a CRN for a MASH IRP. However, funding schemes and sustainability strategies to provide proof-of-platform in MASH seem key in the short-term scenario. Metabolic dysfunction-associated steatohepatitis (MASH) occurs when the liver becomes damaged due to the build up of fat, which is often related to obesity and diabetes. There is a lack of effective drug treatments for MASH, so strategies to strengthen clinical research in this area are needed. Here, we survey key European experts on MASH to assess their interest in joining a network of MASH researchers and their interest in participating in a new type of clinical trial called a platform trial, where multiple drugs can be tested simultaneously. Researchers largely agree that these are promising approaches to boost drug development in the field, although have concerns regarding funding and sustainability strategies. Our findings may inform the creation of a network of MASH researchers capable of running a platform trial, which in turn may speed up research into treatments for MASH. Sena et al. survey European clinical research sites that could potentially serve as the foundation for a MASH integrated research platform and clinical research network. Respondents generally believe that a MASH platform trial could benefit patients and are interested in participating, though securing industry funding is identified as a priority.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes

  • Lazarus, Jeffrey V.|||0000-0001-9618-2299
  • Agirre-Garrido, Leire
  • Díaz, Luis Antonio
  • Danpanichkul, Pojsakorn
  • Kivuyo, Sokoine L.
  • Kondili, Loreta A.
  • Hagström, Hannes
  • Takahashi, Hirokazu
  • Pericàs, Juan M.|||0000-0002-3645-3293
  • Spearman, C. Wendy
  • Oliveira, Claudia P.
  • Villela-Nogueira, Cristiane A.
  • Schattenberg, Jörn M.
  • Toresson Grip, Emilie
  • Alkhouri, Naim
  • Marcellusi, Andrea
  • Mark, Henry E.
  • Allen, Alina M.
  • Carvalho Leite, Nathalie
  • Al-Omar, Hussain A.
  • Alqahtani, Saleh|||0000-0003-2017-3526
  • Brachowicz, Nicolai
What are the most cost-effective management approaches for detecting, preventing, and treating metabolic dysfunction-associated steatohepatitis and liver fibrosis among people living with type 2 diabetes (T2D) in 12 countries? This economic evaluation found that the standard of care had the lowest average cost-effectiveness ratios in 8 countries; intensive lifestyle interventions (ILIs) after screening were cost-effective in all countries; and ILIs and semaglutide or resmetirom therapy were cost-effective in 11 and 7 countries, respectively. In this study, most proposed management approaches among people living with T2D were cost-effective in most countries. This economic evaluation examines which approaches to the detection, prevention, and treatment of metabolic dysfunction-associated steatohepatitis (MASH) among individuals with type 2 diabetes are the most cost-effective across 12 countries, representing all 6 World Health Organization regions. Metabolic dysfunction-associated steatohepatitis (MASH) represents a high, underprioritized burden among noncommunicable diseases (NCDs) and people living with type 2 diabetes (T2D). To identify cost-effective management approaches to prevent, detect, and treat MASH and liver fibrosis in people living with T2D. This economic evaluation consisted of a generalized cost-effectiveness analysis (GCEA) that was conducted for 12 countries (Brazil, Chile, Germany, Italy, Japan, Saudi Arabia, South Africa, Spain, Sweden, Tanzania, Thailand, and the United States), across all 6 World Health Organization (WHO) regions. A cohort state-transition model simulated liver disease development and its impact on a synthetic cohort, aged 19 years and older and living with T2D, over their lifespan across 10 liver health states. Using an 80% coverage level, 14 management approaches were compared, including screening via the Fibrosis-4 (FIB-4) test and Enhanced Liver Fibrosis (ELF) test or vibration-controlled transient elastography (VCTE) as well as treatment with pharmacological and nonpharmacological interventions. The main outcomes were the average cost-effectiveness ratios (ACERs) and the incremental cost-effectiveness ratios (ICERs), which were used to construct care expansion paths by ranking the management approaches in order of cost-effectiveness. The main measures were the total incremental costs and the total incremental quality-adjusted life-years (QALYs) of each intervention. In this GCEA, the outcomes were evaluated with respect to country-specific willingness-to-pay thresholds. The standard of care had the lowest ACERs in 8 countries (not in Chile, Germany, Saudi Arabia, or the United States). Treatment with intensive lifestyle interventions (ILIs), after screening via ELF or VCTE, was cost-effective in all countries. ILIs and treatment with semaglutide was cost-effective in 11 countries (not in Tanzania); ILIs and treatment with resmetirom was cost-effective in 8 countries (not in Brazil, South Africa, Tanzania, or Thailand). In this economic evaluation, screening followed by ILIs was found to be a cost-effective management approach for MASH and liver fibrosis among people living with T2D in all countries. Screening followed by pharmacological treatment was cost-effective in most countries. These results can inform health policy decision-making and further the development of WHO recommended interventions to address NCDs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes, A retrospective case-control study

  • Bañares, Juan|||0000-0002-1966-1947
  • Manzano-Nuñez, Ramiro|||0000-0001-7444-9634
  • Prió, Alba
  • Rivera Esteban, Jesús|||0000-0003-4357-8817
  • Camps-Relats, Laura
  • Villarejo Jiménez, Ana|||0009-0005-7996-9387
  • Ruiz-Ortega, Lourdes|||0000-0003-3636-3367
  • Pons Delgado, Mònica|||0000-0002-0985-3320
  • Ciudin, Andreea|||0000-0001-5622-0203
  • Salcedo, Maria-Teresa|||0000-0002-4822-5060
  • Vargas Blasco, Víctor|||0000-0002-7190-6948
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
  • Pericàs, Juan M.|||0000-0002-3645-3293
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease in developed countries, with its incidence growing parallel to the epidemics of obesity and type 2 diabetes mellitus (T2DM). Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are becoming a cornerstone in the management of cardiovascular health and some studies suggest the potential role in NAFLD. However, patients under treatment with SGLT2i are at risk of developing genitourinary fungal infections (GFIs). Moreover, both NAFLD and SGLT2i have a strong influence on the immune system, and therefore the risk of infections other than GFIs could be increased in NAFLD patients treated with SGLT2i. We aimed to examine the possible association of SGLT2i with infections and hepatic outcomes in NAFLD patients. We conducted a case-control study including NAFLD patients with T2DM visited at the Liver Unit outpatient clinic from 2016 to 2021 with a minimum follow-up of 6 months by selecting 65 patients receiving SGLT2i and 130 matched patients with other types of antidiabetic treatment. During follow-up, GFIs were significantly higher in the SGLT2i group (15.4% vs. 3.8%; p=0.008), whereas there were no differences in the occurrence of overall infections (41.5% vs. 30%; p=0.1) nor in other types of specific infections. In the multivariable analysis, treatment with SGLT2i was not independently associated with higher odds of overall infection. On the other hand, SGLT2i patients showed a significantly lower incidence of hepatic events (1.5% vs. 10.7%; p=0.02). There were no significant different in all-cause mortality between cases and controls. NAFLD patients with T2DM receiving SGLT2i more frequently presented GFIs, whereas the incidence of other types of infections was not found to be higher than in other patients with NAFLD and T2DM treated with other drugs. Moreover, SGLT2i-treated patients had a lower occurrence of hepatic events. Further studies are warranted to validate our data.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Liver steatosis induces portal hypertension regardless of fibrosis in patients with NAFLD, A proof of concept case report